Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch
Brian
B
David Geffen School of Medicine, University of California-Los Angeles (UCLA), Los Angeles, CA 90095-1738, USA.
Li
Zhenhua
Z
Belldegrun
Arie S
AS
D000951:Antigens, Neoplasm / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D009392:Nephrectomy / Q000379:methods; D011379:Prognosis
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007376:Interleukin-2; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases